Interview with Marco Cartolari, CEO, Scharper
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
Address: Viale Ortles, 12 – 20139 Milan (MI),Italy
Tel: +39.02.2629161
Web: http://www.scharper.it/introscharper.htm
Created in 1995 by Dr. Lino Cartolari as La Farmochimica Italiana Srl (LFI), the company then purchased Scharper trademark in 1996 and signs several licensing agreements with different pharma leaders.
Scharper now operates in selected therapeutic areas, and focuses on high profile prescription drugs
(primarily through in-licensing arrangements) as well as highly researched and clinically supported medical foods, nutraceuticals, cosmeceuticals and medical devices( to date developed primarily internally).
Scharper’s focus is unique in that it treats non-drug products with the same scientific scrutiny and rigour as drug products.
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of containment and delivery solutions went public and as an established player in the vaccine space managed…
CAI is an engineering service company. Its regional manager for South Europe, Andrea Castiglioni, comments on the pharma industry’s need for commissioning and qualification services when looking to reduce time…
Merck Italia’s Managing Director & President, Jan Kirsten explains the importance of the Italian affiliate within the global organisation, Merck’s aim to strengthen its position in oncology and the challenges…
Over the past decade, the birth rate in Italy has consistently decreased, making it one of the countries with the lowest birth rates in the world but also one of…
Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic…
Octapharm’s Abramo Brandi, Managing Director of Italy and VP Africa, outlines the particularities of the plasma derivatives business in general and the Italian market in particular. He also explains the…
Ferring Pharmaceuticals’ Federico Gomes de Freitas, General Manager Italy, gives us an overview of how the Italian affiliate fits into the company’s global strategy, especially with respect to reproductive health,…
Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous…
Giorgio Palú, President of the Italian Medicines Agency (AIFA) helps us understand how the agency works, explains the criteria they use to evaluate innovative medicines and tells us about AIFA’s…
Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market. …
SIFI’s Fabrizio Chines outlines how the company is progressing in European ophthalmic markets, explains the added value it is bringing to the glaucoma field, and tells us about its orphan drug…
Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy…
See our Cookie Privacy Policy Here
